1. Home
  2. TD vs JNJ Comparison

TD vs JNJ Comparison

Compare TD & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Toronto Dominion Bank (The)

TD

Toronto Dominion Bank (The)

N/A

Current Price

$94.34

Market Cap

160.3B

Sector

N/A

ML Signal

N/A

Logo Johnson & Johnson

JNJ

Johnson & Johnson

N/A

Current Price

$243.58

Market Cap

589.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TD
JNJ
Founded
1855
1886
Country
Canada
United States
Employees
102218
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
160.3B
589.2B
IPO Year
N/A
2003

Fundamental Metrics

Financial Performance
Metric
TD
JNJ
Price
$94.34
$243.58
Analyst Decision
Buy
Buy
Analyst Count
1
18
Target Price
$120.00
$229.89
AVG Volume (30 Days)
1.6M
7.0M
Earning Date
01-01-0001
04-21-2026
Dividend Yield
3.17%
2.14%
EPS Growth
N/A
90.50
EPS
N/A
11.03
Revenue
N/A
N/A
Revenue This Year
N/A
$6.63
Revenue Next Year
$4.22
$7.23
P/E Ratio
$11.65
$22.06
Revenue Growth
N/A
N/A
52 Week Low
$54.87
$141.50
52 Week High
$99.84
$251.71

Technical Indicators

Market Signals
Indicator
TD
JNJ
Relative Strength Index (RSI) 43.42 58.25
Support Level $93.09 $201.37
Resistance Level $96.41 $251.71
Average True Range (ATR) 1.88 4.12
MACD -0.40 -1.31
Stochastic Oscillator 6.98 51.44

Price Performance

Historical Comparison
TD
JNJ

About TD Toronto Dominion Bank (The)

Toronto-Dominion is one of Canada's two largest banks with over CAD 2 trillion in assets. TD Bank operates four business segments: Canadian personal and commercial banking, US retail banking, wealth management and insurance, and wholesale banking. The bank derives more than 50% of its revenue from Canada and has dominant market share in nearly all banking products and services. TD has around 44% of its revenue from its US operations. Its US footprint spans from Maine to Florida, with a strong presence in the Northeast.

About JNJ Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Share on Social Networks: